Chlornaphazine

From WikiProjectMed
Jump to navigation Jump to search
Chlornaphazine
Names
Preferred IUPAC name
N,N-Bis(2-chloroethyl)naphthalen-2-amine
Other names
Chlornapazine; 2-Naphthylbis(chloroethyl)amine
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
ECHA InfoCard 100.007.078 Edit this at Wikidata
KEGG
UNII
  • InChI=1/C14H15Cl2N/c15-7-9-17(10-8-16)14-6-5-12-3-1-2-4-13(12)11-14/h1-6,11H,7-10H2
    Key: XCDXSSFOJZZGQC-UHFFFAOYAW
  • ClCCN(c2ccc1c(cccc1)c2)CCCl
Properties
C14H15Cl2N
Molar mass 268.18 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Chlornaphazine, a derivative of 2-naphthylamine, is a nitrogen mustard that was developed in the 1950s for the treatment of polycythemia and Hodgkin's disease.[1] However, a high incidence of bladder cancers in patients receiving treatment with chlornaphthazine led to use of the drug being discontinued.[2]

The International Agency for Research on Cancer has listed chlornaphazine as a human carcinogen.[3]

Chlornaphazine appears as a brown solid or as colorless plates and has a boiling point of 210 °C at 5 mmHg.[4]

History

Medical use

Chlornaphazine was clinically used as a cytostatic agent for the treatment of Hodgkin's disease and polycythemia vera in multiple countries including Denmark and Italy.[5]

Discontinued use

Chlornaphazine was discontinued as a clinical drug due to sufficient evidence for carcinogenicity in humans. The drug caused cancer of the urinary bladder. In the Medical Department of the Finsen Institute in Copenhagen, Danish researchers observed many patients over the years with polycythemia vera who had been administered different total doses of chlornaphazine.[6] The initial therapeutic results reported in 1961 indicated that 75% of 32 patients that used chlornaphazine experienced a favorable effect.[6] At the time of the analysis, seven patients died and in the autopsy of one of these patients, a carcinoma of the bladder was accidentally found.[6] In a subsequent study from the Medical Department of the Finsen Institute, 61 patients diagnosed with polycythemia vera that had been treated with chlornaphazine were followed.[5] It was found that among the 61 patients, eight patients developed an invasive carcinoma of the bladder, another eight patients had abnormal urinary cytology, and five patients had developed a papillary carcinoma grade II of the bladder.[5] This led to the discontinuation of chlornaphazine in Denmark in 1963.[7]

Mechanism of action

Chlornaphazine is a nitrogen mustard that was predominantly used in Scandinavia as a treatment for polycythemia and Hodgkin's disease.[8] The possibility of nitrogen mustards to chemically inhibit abnormal cell growth was explored and accelerated through wartime studies of the physiological effects of war gases.[9] The war gas known as nitrogen mustard appeared to be a potential drug for the treatment of leukemia, Hodgkin's disease, and lymphadenopathies in general due to its destructive effect on the bone marrow and particularly on the hemopoietic system.[9] The anti-carcinoma activity of nitrogen mustards is based on their action on mitosis, inhibiting the growth of both normal and abnormal dividing cells.[10] Due to the undesirable side effects of nitrogen mustard, chlornaphazine, another member of the nitrogen mustard series with a similar tumor-inhibiting capacity was developed. Just like the other active nitrogen mustards, chlornaphazine belongs to the direct-acting alkylating agents. It exerts its cytotoxic action by attaching an alkyl group to a lone pair of electrons on an atom of a wide variety of biological molecules by nucleophilic substitution. Through this covalent modification of DNA, chlornaphazine can interfere with essential processes in cancer cells, including DNA replication and protein synthesis.[11] Since this drug is a bifunctional alkylator, it can react at two different sites in the DNA, forming intra- and interstrand cross-links.[11] The structural modifications of DNA caused by chlornaphazine lead to misreading of the DNA code, the inhibition of DNA, RNA, and protein synthesis, and programmed cell death.[12] Cancer cells are among the most affected since alkylating agents have their primary effect on rapidly proliferating cells which do not have time for DNA repair.[12]

Reactivity

The ability to alkylate DNA bases is the predominant aspect of the reactivity of chlornaphazine in the body. The N7 of guanine bases is the preferred position for alkylation since it is the most nucleophilic and accessible site.[13] The mechanism of reaction with DNA proceeds through two successive SN2 reactions in which the N(CH2CH2Cl)2 moiety of chlornaphazine is involved. In the first reaction, the nitrogen acts as a nucleophile to form an aziridinium ion by displacing the halogen.[13] The aziridinium ion is subsequently attacked by nucleophilic sites in DNA. When these two steps are repeated with the second CH2CH2Cl side chain, intra- or interstrand cross-links can be formed.

Metabolism

After oral administration and subsequent absorption, chlornaphazine is metabolized to 2-naphthylamine which is N-acetylated by N-acetyltransferase (NAT) 2 in the liver.[14][15] This is a detoxification reaction since it leads to the formation of non-reactive compounds. Alternatively, CYP1A2, a member of the cytochrome P450 superfamily may convert 2-naphthylamine in its N-hydroxy metabolite.[15] The N-hydroxy metabolite can be further metabolized in the liver or transported to the urinary bladder. In the liver, it can undergo S-glutathionylation catalyzed by glutathione S-transferase Mu 1 (GSTM1), which involves the substitution of the hydroxy group by glutathione.[15] This reaction leads to the detoxification of the N-hydroxy metabolite. The other biotransformation that may occur in the liver is the conjugation with glucuronic acid for which the cosubstrate uridine diphosphate-glucuronic acid (UDPGA) and enzyme UDP-glucuronosyltransferase are required.[16] The stability of the N-glucuronides at neutral pH allows the transport via the blood to the kidneys where they are excreted into the urine.[17] Under the mildly acidic conditions of the urine, the glucuronide is hydrolyzed, liberating the N-hydroxy metabolite in the bladder.[16] The bladder epithelium further activates the N-hydroxy amine to an arylnitrenium ion. A second mechanism through which the N-hydroxy metabolites can be activated to arylnitrenium ions is via NAT1-catalyzed O-acetylation in the bladder.[14] The products of chlornaphazine biotransformation are eliminated in the urine.

Efficacy

Due to its pronounced cytostatic effect, free solubility in water, and easy absorption from the intestinal tract, chlornaphazine appeared to be a suitable treatment for malignant systemic diseases such as Hodgkin's disease and polycythemia vera.[18] Chlornaphazine was an effective medicine for treating fever, weight loss, itching, and sweating which are symptoms of advanced stages of Hodgkin's disease.[18] These beneficial effects were notable when 200-400 mg chlornaphazine was administered daily for months to years.[18] Hodgkin's disease can be treated with chemotherapy consisting of chlornaphazine alone or in combination with other cytostatic drugs.[19] A study that investigated the efficacy of cytostatic treatment for Hodgkin's disease reported that 73% of the patients went into complete remission after receiving cytostatic drugs for 23 months.[19] Chemotherapy can also be combined with radiotherapy. To patients who became resistant to radiation, nitrogen mustards such as chlornaphazine could be administered.[10] In patients with Hodgkin's disease treated with nitrogen mustards tumor masses regressed rapidly.[10] However, tumors reoccurred more rapidly compared to X-ray therapy.[10] Although chlornaphazine was an effective treatment for polycythemia vera, the risks of chlornaphazine were too high making alternative treatments more advantageous.[20]

Adverse effects

Initially, it was reported that chlornaphazine has no major adverse effects since no immediate side effects were found.[18] However, years later, multiple cases were reported of patients treated with chlornaphazine for Hodgkin's disease who were diagnosed with bladder cancer several years after the chlornaphazine treatment had been stopped.[21] In addition, 30% of the polycythemia patients treated with chlornaphazine had developed bladder cancer.[22] These cases and additional research shed light on this alarming side effect of chlornaphazine. It was concluded that chlornaphazine treatment can induce bladder cancer 3 to 10 years after treatment.[23] Development of bladder cancer was only observed in patients who had received a minimal total dose of 100 g chlornaphazine and therefore this late adverse effect is dose-dependent.[6] Common adverse effects of alkylating agents in general are increased risk of malignancy, impaired spermatogenesis, intestinal mucosal damage, alopecia, anemia, pancytopenia, and amenorrhea.[12]

Toxicity

Cancer of the urinary bladder has been observed in many cases treated with chlornaphazine. It has been implied that the carcinogenic effect is caused by the metabolites, whereas the chemotherapeutic action is due to the drug itself.[24] Chlornaphazine contains a nitrogen mustard group at the basic molecule of 2-naphthylamine. The biotransformation of chlornaphazine involves the cleavage of the chloroethyl group, resulting in the formation of 2-naphthylamine.[25] The carcinogenic effect of this compound on the human urinary bladder is well known. The bioactivation of 2-naphthylamine in the liver and urinary bladder results in the formation of products that readily decompose to form reactive arylnitrenium ions. These ions are reactive electrophiles that form adducts by covalently binding to nucleophilic sites on proteins, DNA, and RNA.[14] The tumor induction of chlornaphazine derivatives is specific to the urinary bladder since the carcinogenic metabolites can only be liberated by the acidic environment of urine.

Effects on animals

The mutagenic effects of chornaphazine are studied in multiple animal models. Many studies have shown that rodents are inappropriate animal models to study the carcinogenicity of chlornaphazine due to differences in metabolic pathways between humans and rodents. Therefore, rodents treated with chlornaphazine usually do not develop bladder cancer like humans. Chlornaphazine was shown to cause chromosomal abnormalities in Chinese hamster lung cells, mutations in lymphoma cells of mice, and spontaneous in vitro synthesis of DNA in rat hepatocytes.[26][27] In addition, chlornaphazine induces chromosomal abnormalities in erythrocytes in both mouse and rat bone marrow.[27] It has been reported that chornaphazine is a genetic hazard to the offspring of mice previously exposed to this drug since it is highly mutagenic in post-meiotic male germ cells.[28] Moreover, mice injected with chlornaphazine intraperitoneally developed lung tumors whereas rats injected with chlornaphazine subcutaneously developed local sarcomas.[29] In contrast to rodents, dogs are suitable for studying bladder carcinogens, such as chlornaphazine, since the metabolism of aromatic amines in dogs is similar to that in humans due to the comparable urine pH and urination frequency of both species.[30] Animal experiments had also been performed to expand the knowledge of the carcinogenic effects of chlornaphazine's metabolite 2-naphthylamine. Like in humans, 2-naphthylamine induces bladder tumors in dogs,[31][32] monkeys,[33] and hamsters.[34] Bladder cancer can be induced in rats, but 2-naphthylamine is a very weak carcinogen in rats due to their urine pH, urination frequency, and resorption.[30][35] In mice, 2-naphthylamine caused an increase in hepatomas, liver adenomas, and cholangiomas.[36][37]

References

  1. ^ Videbaek, A.; Kaae, S. (1954). "2-Naphthylbis(chloroethyl)amine in the treatment of malignant diseases, particularly Hodgkin's disease". Acta Medica Scandinavica. 149 (5): 361–368. doi:10.1111/j.0954-6820.1954.tb11446.x. PMID 13180246.
  2. ^ Benedicte Laursen (1970). "Cancer of the Bladder in Patients Treated with Chlornaphazine". Br Med J. 3 (5724): 684–685. doi:10.1136/bmj.3.5724.684. PMC 1701774. PMID 5470116.
  3. ^ N,N-Bis(2-Chloroethyl)-2-Naphthylamine (Chlornaphazine), International Agency for Research on Cancer
  4. ^ PubChem. "Chlornaphazine". pubchem.ncbi.nlm.nih.gov.
  5. ^ a b c Humans, IARC Working Group on the Evaluation of Carcinogenic Risks to (2012). CHLORNAPHAZINE. International Agency for Research on Cancer.
  6. ^ a b c d Thiede, Torben; Chievitz, Eva; Christensen, Børge Chr. (1964). "Chlornaphazine as a Bladder Carcinogen". Acta Medica Scandinavica. 175 (6): 721–725. doi:10.1111/j.0954-6820.1964.tb00628.x. PMID 14171978.
  7. ^ Konz, J. (1994). SUBJECT: Review of ERM's Cancer Risk Assessment and Recommendations for Alternative Provisional Qualitative and Quantitative Assessments. Drake Chemical/Lock Haven, PA. p. 94.
  8. ^ Clark, T. J. H. (1970). "Inspiratory Obstruction". BMJ. 3 (5724): 682–684. doi:10.1136/bmj.3.5724.682. ISSN 0959-8138. PMC 1701769. PMID 5470115.
  9. ^ a b Davis, W. (1957). Some attempts at chemotherapy of cancer. Postgraduate Medical Journal. p. 540.
  10. ^ a b c d Garai, O. (1948). "Nitrogen Mustard". Postgraduate Medical Journal. 24 (272): 307–311. doi:10.1136/pgmj.24.272.307. ISSN 0032-5473. PMC 2529779. PMID 18864652.
  11. ^ a b Bordin, Diana L.; Lima, Michelle; Lenz, Guido; Saffi, Jenifer; Meira, Lisiane B.; Mésange, Paul; Soares, Daniele G.; Larsen, Annette K.; Escargueil, Alexandre E.; Henriques, João A. P. (2013). "DNA alkylation damage and autophagy induction". Mutation Research/Reviews in Mutation Research. 753 (2): 91–99. doi:10.1016/j.mrrev.2013.07.001. ISSN 1383-5742. PMID 23872363.
  12. ^ a b c "Alkylating Agents", LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, 2012, PMID 31643188
  13. ^ a b Karmakar, Subhendu; Maji, Moumita; Mukherjee, Arindam (2019). "Modulation of the reactivity of nitrogen mustards by metal complexation: approaches to modify their therapeutic properties". Dalton Transactions. 48 (4): 1144–1160. doi:10.1039/C8DT04503H. ISSN 1477-9234. PMID 30629051. S2CID 58571271.
  14. ^ a b c Wang, Shuang; Hanna, Daniel; Sugamori, Kim S.; Grant, Denis M. (2019). "Primary aromatic amines and cancer: Novel mechanistic insights using 4-aminobiphenyl as a model carcinogen". Pharmacology & Therapeutics. 200: 179–189. doi:10.1016/j.pharmthera.2019.05.004. ISSN 0163-7258. PMID 31075357. S2CID 149454319.
  15. ^ a b c Antonova, O; Toncheva, D; Grigorov, E (2015). Bladder cancer risk from the perspective of genetic polymorphisms in the carcinogen metabolizing enzymes. Journal of B.U.ON.: official journal of the Balkan Union of Oncology. pp. 1397–1406.
  16. ^ a b Freudenthal, Ralph I.; Stephens, Ellen; Anderson, Daniel P. (1999). "Determining the Potential of Aromatic Amines to Induce Cancer of the Urinary Bladder". International Journal of Toxicology. 18 (5): 353–359. doi:10.1080/109158199225260. ISSN 1091-5818. S2CID 86180301.
  17. ^ Poupko, Jay M.; Hearn, William Lee; Radomski, Jack L. (1979). "N-Glucuronidation of N-hydroxy aromatic amines: A mechanism for their transport and bladder-specific carcinogenicity". Toxicology and Applied Pharmacology. 50 (3): 479–484. doi:10.1016/0041-008X(79)90401-0. ISSN 0041-008X. PMID 516060.
  18. ^ a b c d VIDEBaeK, Aage (1964). "Ghlornaphazin (Erysan®) May Induce Cancer of the Urinary Bladder". Acta Medica Scandinavica. 176 (1): 45–50. doi:10.1111/j.0954-6820.1964.tb00643.x.
  19. ^ a b Andersen, E.; Christensen, B. Egelund; Videbaek, Aa. (1972). "Treatment of Hodgkin's Disease: Results Obtained by Individualized Treatment Using Radiotherapy and Cytostatics". Scandinavian Journal of Haematology. 9 (1–6): 625–638. doi:10.1111/j.1600-0609.1972.tb00994.x. PMID 4630133.
  20. ^ Schottenfeld, D. (1982). "Cancer Risks of Medical Treatment". CA: A Cancer Journal for Clinicians. 32 (5): 258–279. doi:10.3322/canjclin.32.5.258. ISSN 0007-9235. S2CID 221546560.
  21. ^ Laursen, B. (1970). "Cancer of the Bladder in Patients Treated with Chlornaphazine". BMJ. 3 (5724): 684–685. doi:10.1136/bmj.3.5724.684. ISSN 0959-8138. PMC 1701774. PMID 5470116.
  22. ^ Schmähl, D. (1981). "Iatrogenic carcinogenesis". Journal of Cancer Research and Clinical Oncology. 99 (1–2): 71–75. doi:10.1007/BF00412444. ISSN 0171-5216. PMID 7251640. S2CID 33262182.
  23. ^ Thiede, Torben; Christensen, Børge Chr. (1969). "BLADDER TUMOURS INDUCED BY CHLORNAPHAZINE: A Five-year Follow-up Study of Chlornaphazine-treated Patients with Polycythaemia". Acta Medica Scandinavica. 185 (1–6): 133–137. doi:10.1111/j.0954-6820.1969.tb07309.x. PMID 5257690.
  24. ^ Boyland, E (1967). Biochemical Aspects of Carcinogenesis with Special Reference to Alkylating Agents and Some Antibiotics. Berlin, Heidelberg: Potential Carcinogenic Hazards from Drugs. pp. 204–208.
  25. ^ Habs, M; Schmähl, D (1984). Long-term Toxic and Carcinogenic Effects of Cytostatic Drugs. Heidelberg: German Cancer Research Center. p. 201.
  26. ^ Genetic and related effects: An updating of selected IARC monographs from Volumes 1 to 42. IARC Monogr Eval Carcinog Risks Hum Suppl. 1987. pp. 1–729.
  27. ^ a b Ashby, J.; Loquet, C.; Ishidate, M.; Callander, R. D.; Albanese, R. (1988). "Mutagenicity to bacteria, cultured cells, and rodents of the human carcinogen chlornaphazine". Environmental Mutagenesis. 12 (4): 365–374. doi:10.1002/em.2860120405. PMID 3056719.
  28. ^ Barnett, Lois B; Lewis, Susan E (2003). "Chlornaphazine and chlorambucil induce dominant lethal mutations in male mice". Mutation Research/Reviews in Mutation Research. Special Issue in Honor of James V. Neel. 543 (2): 145–154. doi:10.1016/S1383-5742(03)00012-7. ISSN 1383-5742. PMID 12644184.
  29. ^ Hottendorf, Girard H. (1985). "Carcinogenicity Testing of Antitumor Agents". Toxicologic Pathology. 13 (3): 192–199. doi:10.1177/019262338501300305. ISSN 0192-6233. PMID 4070930. S2CID 29805276.
  30. ^ a b Young, J.F.; Kadlubar, F.F. (1982). A pharmacokinetic model to predict exposure of the bladder epithelium to urinary N-hydroxyarylamine carcinogens as a function of urine pH, voiding interval, and resorption. Drug Metab Dispos. pp. 641–644.
  31. ^ Conzelman, G.M. Jr; Moulton, J.E. (1972). Dose-response relationships of the bladder tumorigen 2-naphthylamine: a study in beagle dogs. J Natl Cancer Inst. pp. 193–205.
  32. ^ Purchase, I F; Kalinowski, A E; Ishmael, J; Wilson, J; Gore, C W; Chart, I S (1981). "Lifetime carcinogenicity study of 1- and 2-naphthylamine in dogs". British Journal of Cancer. 44 (6): 892–901. doi:10.1038/bjc.1981.289. ISSN 0007-0920. PMC 2010866. PMID 7326199.
  33. ^ Conzelman, G.M Jr; Moulton, J.E.; Flanders, L.E.; Springer, K; Crout, D.W. (1969). Induction of transitional cell carcinomas of the urinary bladder in monkeys fed 2-naphthylamine. J Natl Cancer Inst. pp. 825–836.
  34. ^ Saffiotti, U; Cefis, F; Montesano, R; Sellakumar, A (1967). Induction of bladder cancer in hamsters fed aromatic amines. Bladder Cancer:. Deichmann, W., Lampe, KG, editors. pp. 129–135.
  35. ^ Hicks, R M; Wright, R; Wakefield, J S J (1982). "The induction of rat bladder cancer by 2-naphthylamine". British Journal of Cancer. 46 (4): 646–661. doi:10.1038/bjc.1982.250. ISSN 0007-0920. PMC 2011196. PMID 7138770.
  36. ^ Bonser, Georgiana M; Clayson, D B; Jull, J W (1956). "The Induction of Tumours of the Subcutaneous Tissues, Liver and Intestine in the Mouse by Certain Dyestuffs and their Intermediates". British Journal of Cancer. 10 (4): 653–667. doi:10.1038/bjc.1956.79. ISSN 0007-0920. PMC 2073864. PMID 13426377.
  37. ^ Yoshida, M; Numoto, S; Otsuka, H (1979). Histopathological changes induced in the urinary bladder and liver of female BALB/c mice treated simultaneously with 2-naph-thylamine and cyclophosphamide. Gan. pp. 645–652.
Retrieved from "https://mdwiki.org/wiki/Chlornaphazine"